{Reference Type}: Practice Guideline
{Title}: Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria.
{Author}: Pintado V;Ruiz-Garbajosa P;Aguilera-Alonso D;Baquero-Artigao F;Bou G;Cantón R;Grau S;Gutiérrez-Gutiérrez B;Larrosa N;Machuca I;Martínez Martínez L;Montero MM;Morte-Romea E;Oliver A;Paño-Pardo JR;Sorlí L;
{Journal}: Enferm Infecc Microbiol Clin (Engl Ed)
{Volume}: 41
{Issue}: 6
{Year}: Jun-Jul 2023 13
暂无{DOI}: 10.1016/j.eimce.2022.06.014
{Abstract}: Infections caused by multidrug resistant Gram-negative bacteria are becoming a worldwide problem due to their increasing incidence and associated high mortality. Carbapenem-resistant bacteria such as Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii are the most important in clinical practice. The objective of these guidelines is to update the recommendations for the diagnosis and treatment of infections caused by these multidrug resistant bacteria. Although 'old' antibiotics such as aminoglycosides, colistin, or tigecycline are frequently used for therapy of these bacteria, the 'new' beta-lactams such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam or cefiderocol are progressively becoming the first-line therapy for most of these microorganisms. The Spanish Society of Infectious Diseases and Clinical Microbiology (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica) designated a panel of experts in the field to provide evidence-based recommendations in response to common clinical questions. This document is primarily focused on microbiological diagnosis, clinical management, and targeted antimicrobial therapy of these infections, with special attention to defining the role of the new antimicrobials in the treatment of these bacteria.